Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Jan 12;54(1):11-13.
doi: 10.1016/j.immuni.2020.12.012.

Spliceosome-Targeted Therapies Induce dsRNA Responses

Charles A Ishak  1 , Helen Loo Yau  2 , Daniel D De Carvalho  3
Affiliations
Free article
Comment

Spliceosome-Targeted Therapies Induce dsRNA Responses

Charles A Ishak et al. Immunity. .
Free article

Abstract

In a recent issue of Cell, Bowling et al. describe a mechanism by which spliceosome-targeted therapies result in intron-containing transcripts that form double-stranded RNAs (dsRNAs), thereby activating tumor antiviral signaling (viral mimicry) and downstream adaptive immunity.

PubMed Disclaimer

Conflict of interest statement

Declaration of Interests D.D.D.C. received research funding from Pfizer and Nektar Therapeutics and is co-founder, shareholder, and consultant for DNAMx. The other authors declare no competing interests

Comment on

  • Spliceosome-targeted therapies trigger an antiviral immune response in triple-negative breast cancer.
    Bowling EA, Wang JH, Gong F, Wu W, Neill NJ, Kim IS, Tyagi S, Orellana M, Kurley SJ, Dominguez-Vidaña R, Chung HC, Hsu TY, Dubrulle J, Saltzman AB, Li H, Meena JK, Canlas GM, Chamakuri S, Singh S, Simon LM, Olson CM, Dobrolecki LE, Lewis MT, Zhang B, Golding I, Rosen JM, Young DW, Malovannaya A, Stossi F, Miles G, Ellis MJ, Yu L, Buonamici S, Lin CY, Karlin KL, Zhang XH, Westbrook TF. Bowling EA, et al. Cell. 2021 Jan 21;184(2):384-403.e21. doi: 10.1016/j.cell.2020.12.031. Epub 2021 Jan 14. Cell. 2021. PMID: 33450205 Free PMC article.